Literature DB >> 22944067

The clinical significance of inflammatory cytokines in primary cell culture in endometrial carcinoma.

Harriet O Smith1, Nicole D Stephens, Clifford R Qualls, Tal Fligelman, Tao Wang, Chang-Yun Lin, Elizabeth Burton, Jeffrey K Griffith, Jeffrey W Pollard.   

Abstract

Endometrial cancer is the most common malignancy of the female genital tract, and the incidence and mortality rates from this disease are increasing. Although endometrial carcinoma has been regarded as a tissue-specific disease mediated by female sex steroid pathways, considerable evidence implicates a role for an inflammatory response in the development and propagation of endometrial cancer. We hypothesized that if specific patterns of cytokine expression were found to be predictive of adverse outcome, then selective receptor targeting may be a therapeutic option. This study was therefore undertaken to determine the relationship between cytokine production in primary cell culture and clinical outcome in endometrial adenocarcinoma. Fresh endometrial tissues were fractionated into epithelial and stromal fractions and cultured. After 6-7 days, supernatants were collected and cells enumerated. Batched aliquots were assayed using ELISA kits specific for CSF-1, GMCSF, G-CSF, TNF-α, IL-6, IL-8, and VEGF. Data were compared using ANOVA, Fisher's exact, and log rank tests. Increased epithelial VEGF production was observed more often in tumors with Type 2 variants (p = 0.039) and when GPR30 receptor expression was high (p = 0.038). Although increased stromal VEGF production was detected more often in grade 3 endometrioid tumors (p = 0.050), when EGFR expression was high (p = 0.003), and/or when ER/PR expression was low (p = 0.048), VEGF production did not correlated with overall survival (OS). Increased epithelial CSF-1 and TNF-α production, respectively, were observed more often in tumors with deep myometrial invasion (p = 0.014) and advanced stage (p = 0.018). Increased CSF-1 (89.5% vs. 42.9%, p = 0.032), TNF-α (88.9% vs. 42.9%, p = 0.032, and IL-6 (92.3% vs. 61.5%, p = 0.052) also correlated with low OS. In Cox multivariate models, CSF-1 was an independent predictor of low survival when stratified by grade (p = 0.046) and histology (p = 0.050), and TNF-α, when stratified by histology (p = 0.037). In this study, high CSF-1, TNF-α, and IL-6 production rates identified patients at greatest risk for death, and may signify patients likely to benefit from receptor-specific therapy.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22944067      PMCID: PMC3790272          DOI: 10.1016/j.molonc.2012.07.002

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  46 in total

1.  Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma.

Authors:  Carien L Creutzberg; Remi A Nout; Marnix L M Lybeert; Carla C Wárlám-Rodenhuis; Jan J Jobsen; Jan-Willem M Mens; Ludy C H W Lutgens; Elisabeth Pras; Lonneke V van de Poll-Franse; Wim L J van Putten
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-02       Impact factor: 7.038

2.  The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial.

Authors:  C L Creutzberg; W L van Putten; P C Koper; M L Lybeert; J J Jobsen; C C Wárlám-Rodenhuis; K A De Winter; L C Lutgens; A C van den Bergh; E van der Steen-Banasik; H Beerman; M van Lent
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-12-01       Impact factor: 7.038

3.  Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy.

Authors:  R J Tushinski; I T Oliver; L J Guilbert; P W Tynan; J R Warner; E R Stanley
Journal:  Cell       Date:  1982-01       Impact factor: 41.582

4.  Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.

Authors:  Rebecca Siegel; Elizabeth Ward; Otis Brawley; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-06-17       Impact factor: 508.702

5.  Interleukin-6 as a therapeutic target in human ovarian cancer.

Authors:  Jermaine Coward; Hagen Kulbe; Probir Chakravarty; David Leader; Vessela Vassileva; D Andrew Leinster; Richard Thompson; Tiziana Schioppa; Jeffery Nemeth; Jessica Vermeulen; Naveena Singh; Norbert Avril; Jeff Cummings; Elton Rexhepaj; Karin Jirström; William M Gallagher; Donal J Brennan; Iain A McNeish; Frances R Balkwill
Journal:  Clin Cancer Res       Date:  2011-07-27       Impact factor: 12.531

Review 6.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

7.  Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.

Authors:  Barbara Mroczko; Magdalena Groblewska; Urszula Wereszczyńska-Siemiatkowska; Bogna Okulczyk; Bogusław Kedra; Wiktor Łaszewicz; Andrzej Dabrowski; Maciej Szmitkowski
Journal:  Clin Chim Acta       Date:  2007-02-27       Impact factor: 3.786

8.  The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma.

Authors:  H O Smith; P S Anderson; D Y Kuo; G L Goldberg; C L DeVictoria; C A Boocock; J G Jones; C D Runowicz; E R Stanley; J W Pollard
Journal:  Clin Cancer Res       Date:  1995-03       Impact factor: 12.531

9.  Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.

Authors:  E Y Lin; A V Nguyen; R G Russell; J W Pollard
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

10.  Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.

Authors:  C A Hamilton; M K Cheung; K Osann; L Chen; N N Teng; T A Longacre; M A Powell; M R Hendrickson; D S Kapp; J K Chan
Journal:  Br J Cancer       Date:  2006-03-13       Impact factor: 7.640

View more
  19 in total

Review 1.  Molecular cues on obesity signals, tumor markers and endometrial cancer.

Authors:  Danielle Daley-Brown; Gabriela M Oprea-Ilies; Regina Lee; Roland Pattillo; Ruben R Gonzalez-Perez
Journal:  Horm Mol Biol Clin Investig       Date:  2015-01

2.  Has the time come to include low-level laser photobiomodulation as an adjuvant therapy in the treatment of impaired endometrial receptivity?

Authors:  Doaa Abdelmageed El Faham; Mohamed Amr Hussein Elnoury; Mona Ibraheim Morsy; Marwa Abdelmoneim El Shaer; Ghada Mohammed Nour Eldin; Osama Mahmoud Azmy
Journal:  Lasers Med Sci       Date:  2018-03-15       Impact factor: 3.161

3.  Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability.

Authors:  Carlos Murga-Zamalloa; Delphine C M Rolland; Avery Polk; Ashley Wolfe; Hiran Dewar; Pinki Chowdhury; Ozlem Onder; Rajan Dewar; Noah A Brown; Nathanael G Bailey; Kedar Inamdar; Megan S Lim; Kojo S J Elenitoba-Johnson; Ryan A Wilcox
Journal:  Clin Cancer Res       Date:  2019-10-21       Impact factor: 12.531

4.  Cancer-associated fibroblasts promote endometrial cancer growth via activation of interleukin-6/STAT-3/c-Myc pathway.

Authors:  Kavita S Subramaniam; Intan Sofia Omar; Soke Chee Kwong; Zahurin Mohamed; Yin Ling Woo; Noor Azmi Mat Adenan; Ivy Chung
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

5.  The clinical significance of inflammatory cytokines in primary cell culture in endometrial carcinoma.

Authors:  Harriet O Smith; Nicole D Stephens; Clifford R Qualls; Tal Fligelman; Tao Wang; Chang-Yun Lin; Elizabeth Burton; Jeffrey K Griffith; Jeffrey W Pollard
Journal:  Mol Oncol       Date:  2012-08-15       Impact factor: 6.603

Review 6.  Tumor-associated macrophages: from mechanisms to therapy.

Authors:  Roy Noy; Jeffrey W Pollard
Journal:  Immunity       Date:  2014-07-17       Impact factor: 31.745

7.  Estrogen mediated expression of nucleophosmin 1 in human endometrial carcinoma clinical stages through estrogen receptor-α signaling.

Authors:  Yunxiao Zhou; Jie Shen; Liqun Xia; Yanli Wang
Journal:  Cancer Cell Int       Date:  2014-12-20       Impact factor: 5.722

Review 8.  Targeting macrophages: therapeutic approaches in cancer.

Authors:  Luca Cassetta; Jeffrey W Pollard
Journal:  Nat Rev Drug Discov       Date:  2018-10-26       Impact factor: 84.694

9.  HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs).

Authors:  Ernestina Marianna De Francesco; Rosamaria Lappano; Maria Francesca Santolla; Stefania Marsico; Arnaldo Caruso; Marcello Maggiolini
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

10.  Increased Expression of CSF-1 Associates With Poor Prognosis of Patients With Gastric Cancer Undergoing Gastrectomy.

Authors:  Hao Liu; Heng Zhang; Zhenbin Shen; Chao Lin; Xuefei Wang; Jing Qin; Xinyu Qin; Jiejie Xu; Yihong Sun
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.